Form 4 for TRDA Entrada Therapeutics, Inc.
Accepted 2024-05-20 00:00:00 ET · period of report 2024-05-16 · accession 0001689375-24-000030 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-05-20 | 2024-05-16+ | TRDA | Doshi Dipal | CEO, Dir | S - Sale | $15.04 | -3,000 | 337.4K | -0.9% | -$45.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-16 | S | D | 1,800 | $15.00 | 338,575 | D | — | — | |
| 2 | Common | Common Stock | 2024-05-17 | S | D | 1,200 | $15.11 | 337,375 | D | — | — |